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new Vaccine Formulations 
containing a Modified Version of the 
amastigote 2 antigen and the non-
Virulent Trypanosoma cruzi cl-14 
strain are highly antigenic and 
Protective against Leishmania 
infantum challenge
Ana Paula M. M. Almeida1‡, Leopoldo F. M. Machado1,2†‡, Daniel Doro1,2†, 
Frederico C. Nascimento1, Leonardo Damasceno3, Ricardo Tostes Gazzinelli2,4, 
Ana Paula Fernandes1* and Caroline Junqueira2*
1 Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo 
Horizonte, Brazil, 2 Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil, 3 Hertape Saúde Animal S.A., Ceva 
Saúde Animal Ltda, Juatuba, Brazil, 4 Division of Infectious Disease, University of Massachusetts Medical School, Worcester, 
MA, United States
Visceral leishmaniasis (VL) is a major public health issue reported as the second illness 
in mortality among all tropical diseases. Clinical trials have shown that protection against 
VL is associated with robust T cell responses, especially those producing IFN-γ. The 
Leishmania amastigote 2 (A2) protein has been repeatedly described as immunogenic 
and protective against VL in different animal models; it is recognized by human T cells, 
and it is also commercially available in a vaccine formulation containing saponin against 
canine VL. Moving toward a more appropriate formulation for human vaccination, 
here, we tested a new optimized version of the recombinant protein (rA2), designed for 
Escherichia coli expression, in combination with adjuvants that have been approved for 
human use. Moreover, aiming at improving the cellular immune response triggered by 
rA2, we generated a recombinant live vaccine vector using Trypanosoma cruzi CL-14 
non-virulent strain, named CL-14 A2. Mice immunized with respective rA2, adsorbed 
in Alum/CpG B297, a TLR9 agonist recognized by mice and human homologs, or with 
the recombinant CL-14 A2 parasites through homologous prime-boost protocol, were 
evaluated for antigen-specific immune responses and protection against Leishmania 
infantum promastigote challenge. Immunization with the new rA2/Alum/CpG formula-
tions and CL-14 A2 transgenic vectors elicited stronger cellular immune responses than 
control groups, as shown by increased levels of IFN-γ, conferring protection against 
L. infantum challenge. Interestingly, the use of the wild-type CL-14 alone was enough to 
boost immunity and confer protection, confirming the previously reported immunogenic 
potential of this strain. Together, these results support the success of both the newly 
designed rA2 antigen and the ability of T. cruzi CL-14 to induce strong T cell-mediated 
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immune responses against VL in animal models when used as a live vaccine vector. In 
conclusion, the vaccination strategies explored here reveal promising alternatives for the 
development of new rA2 vaccine formulations to be translated human clinical trials.
Keywords: visceral leishmaniasis, vaccine, Trypanosoma cruzi cl-14, Leishmania infantum, amastigote 2
inTrODUcTiOn
Visceral leishmaniasis (VL) is an infectious disease that affects 
mainly splenic and hepatic systems, being the second among 
the parasitic infections with highest mortality rates. This vector-
borne tropical infection is caused by a flagellate protozoan of 
the genus Leishmania spp and affects more than 200,000 people 
per year (1). Failure to develop a potent human vaccine against 
this pathogen lies in the complexity of the immune response to 
the intracellular stage of parasite, given its previously reported 
defense mechanisms against innate and adaptive immunity (2).
The induction of a strong and long-lasting T helper type 1 
(Th1) cellular immune response with high levels of IFN-γ pro-
duction is a key feature, desired in ideal vaccine candidates. IFN-γ 
knockout mice fail to overcome infection with Leishmania species 
to which most immunocompetent mouse lines are resistant (3). 
In addition, IFN-γ is known to induce macrophage activation by 
increasing nitric oxide (NO) synthesis, leading to NO-mediated 
killing of intracellular pathogens (4).
The amastigote 2 (A2) proteins are mostly composed of a 
sequence of 10 amino acids that is repeated 40–90 times with 
molecular weights varying from 45 to 100 kDa (5). The A2 protein 
plays an important role in Leishmania survival in visceral organs, 
since the growth of A2-deficient amastigotes of Leishmania dono­
vani into visceral organs was severely impaired when compared 
to A2-containing amastigotes (6). Similarly, the introduction of 
the L. donovani A2 gene into Leishmania major enhanced the 
ability of the latter to survive in visceral organs (7).
The recombinant A2 protein is recognized by human T cells 
(8) and has been reported as a vaccine candidate in different 
strains of mice using different vaccine formulations and delivery 
methods (9–11). In association with saponin, it was shown to 
induce protection against VL in beagle dogs (12). In all of these 
studies, protection was accompanied by a strong Th1 immune 
response with high levels of IFN-γ. In addition, successful vac-
cination against canine VL has been achieved in the previous 
years with the administration of Leish-Tec®, a commercial vac-
cine formulated with A2 (13, 14). However, due to its repeat-rich 
sequence, the expression and purification of recombinant A2 
can be a laborious and time-consuming process. In this study, 
we optimized the A2 gene sequence for expression in Escherichia 
coli, including the entire non-repetitive domain of the protein and 
10 repeated regions, in contrast with 40–90 repetitions from the 
original sequence.
Live vaccine vectors have been shown to improve T  cell 
immune responses elicited by different antigens against several 
parasitic diseases (15, 16), including the A2 antigen (10). The 
Trypanosoma cruzi CL-14 non-virulent strain has been previously 
shown to be highly immunogenic in mouse models with produc-
tion of high levels of IFN-γ and transient expansion of splenic 
CD8+ T cells (17, 18). Moreover, a single injection of CL-14 has 
been shown to induce protection against lethal T. cruzi challenge 
using the highly virulent Y strain in BALB/c mice (19). To date, 
no studies have addressed whether immunization with CL-14 is 
enough to induce protection against VL challenge although both 
pathogens share a vast proteomic core and similar biology (20, 21). 
A previous study from our group tested the CL-14 strain as a 
vaccine vector, becoming a promising antigen delivery strategy 
to boost Th1 antigen-specific immune response (18).
To further explore the potential of A2 as a candidate antigen 
for human VL vaccines, we tested an optimized rA2 in combina-
tion with adjuvants approved for human vaccination. In addi-
tion, we generated stably transfected T. cruzi CL-14 expressing 
A2. Our data suggest that the newly designed rA2, formulated 
either with monophosphoryl lipid A (MPLA) or the synthetic 
oligodeoxynucleotides (ODNs) CpG B297, as well as the live 
vector T. cruzi CL-14 vaccine, can elicit robust antileishmaniasis 
immune responses. While the recombinant protein formulation 
has proven to be a good candidate to progress to human clinical 
trials, the live CL-14 vector vaccine may be a future alternative 
to achieve the prophylaxis of leishmaniasis and Chagas disease.
MaTerials anD MeThODs
Parasites
Epimastigote forms of non-pathogenic T. cruzi CL-14 were cul-
tured in liver infusion tryptose medium supplemented with 10% 
fetal bovine serum (FBS) (Gibco, USA), 10,000 U/mL penicillin, 
and 10 mg/mL streptomycin (Gibco, USA) at 28°C in a biochemi-
cal oxygen demand (BOD) incubator. The transgenic parasites 
obtained were cultured in the same conditions with addition of 
250  µg/mL geneticin (Gibco, USA) for selection of neomycin-
resistant parasites. To perform immunization protocols, parasites 
were kept in stationary culture for 15–20 days, aiming to obtain 
metacyclic forms. Promastigotes of Leishmania infantum (MOM/
BR/1970/BH46) were cultured in Schneider’s Insect medium 
(Sigma Aldrich, USA) supplemented with 10% FBS, 10,000 U/mL 
penicillin, and 10 mg/mL streptomycin at 26°C in a BOD incubator.
Mice and ethics statement
Female BALB/c mice, 6- to 8-week-old mice were purchased 
from the Institute of Biological Sciences at Federal University of 
Minas Gerais (Belo Horizonte, Brazil). Mouse experiments were 
approved by and conducted according to animal welfare guide-
lines of the Ethics Committee of Animal Experimentation from 
Federal University of Minas Gerais, under the approved protocol 
number 73/2009.
antigen expression and Purification
To improve the A2 protein expression and purification protocols, 
without impairing the immunological outcome generated by 
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this antigen, we constructed an E. coli codon-optimized gene 
containing a selected nucleotide sequence spanning the entire 
coding region of the A2 protein. This improved gene contains 
10, instead of the 40–90 repeated regions present in the original 
L. infantum A2 gene (XM_001465551) (22) and additional codons 
for a C-terminal 6× His tag. The synthetic gene was further 
cloned, through restriction enzyme digestion, into the pET9a 
vector to originate the plasmid pET9a24a-A2His, which was then 
transformed into E. coli C41 cells.
Protein expression was induced by IPTG. After induction, 
cells were harvested by centrifugation and lysed by sonication. 
The supernatant was then used for purification under denatura-
tion conditions in a HisTrap column (GE Healthcare, UK) using 
the Äkta prime system. The purified protein was submitted to a 
second purification step using a HiTrap™SepharoseTM HP Ion 
Exchange column (GE Healthcare, UK). Finally, the purified 
fraction was loaded in an EndoTrap® HD column (Hyglos, DE) 
to remove endotoxins. The final purified protein was analyzed 
in Coomassie-stained SDS-PAGE, and its specific reactivity was 
assessed by western blot analysis using an anti-A2 monoclonal 
antibody, kindly provided by Dr. Greg Matlashewski.
Parasite construction and 
characterization
The codon-optimized A2 gene was isolated and cloned into the 
pROCKNeo plasmid using the XhoI and XbaI restriction sites. The 
resulting plasmid, pROCKNeoA2His (Figure S1 in Supplementary 
Material) was then used to transfect T. cruzi epimastigotes, as pre-
viously described (23). To achieve an integrative transfection into 
the parasite genome, the plasmids were linearized with NotI prior to 
electroporation. After transfection, the parasites were selected for 
neomycin resistance by addition of geneticin (G418) into culture 
medium. The presence of the A2 gene into the selected parasites 
was assessed by conventional PCR using: forward primer: HX1-5′ 
TTCTTCAAAATATGCAGCGGATT 3′ and reverse primer for 
A2: A2NOTRV-5′ TACCGCGGCCGCCTAGTGGTGATGG 3′.
Expression of the A2 protein in the recombinant T. cruzi 
CL-14 A2 parasite was assessed by both western blot and immu-
nofluorescence analysis. For western blot analyses, the cell lysates 
of 2 × 107 epimastigotes of T. cruzi CL-14 or T. cruzi CL-14 A2 
were submitted to SDS-PAGE and then transferred to a 0.45-μm 
nitrocellulose membrane (GE Healthcare, UK). To detect A2 
expression by the T. cruzi CL-14 A2, we used a 1:100 dilution 
of anti-A2 monoclonal antibody. As the secondary antibody, we 
used anti-mouse anti-IgG horseradish peroxidase-conjugated 
antibody (Sigma Aldrich USA). The chemiluminescence reagent 
ECL Prime (GE Healthcare, UK) was used to reveal the reactions. 
The membranes were analyzed by an IS600 image system (GE 
Healthcare, UK).
For immunofluorescence analysis, 2  ×  105 parasites were 
washed, fixed [phosphate-buffered saline (PBS)  +  2% para-
formaldehyde], loaded into a poly-l-lysine-coated glass slide, 
and incubated overnight at room temperature. The cells were 
then rehydrated and permeabilized with Triton X-100 0.2% in 
PBS. The monoclonal anti-A2 antibody was used as a primary 
antibody. Secondary antibody Alexa Fluor® 488 anti-mouse IgG 
(Thermo Scientific, USA) was used. After five wash steps, we added 
Vectashield containing DAPI to each spot (Vector Laboratories, 
USA). The glass slides were analyzed in a LSM Zeiss microscope.
immunization Protocols and challenge
For the immunization protocols, BALB/c mice (n =  10) were 
vaccinated with homologous prime-boost protocols. For the 
immunization groups receiving the recombinant protein, the 
following formulations were used: 10  µg of rA2 associated 
with 18  µg of CpG B297 (24) adsorbed in 30% (v/v) of Alum 
Rehydragel LV solution (Reheis, USA) or 10 µg of rA2 associ-
ated with 1.0 µg of MPLA (Butantan, Brazil). A total volume of 
100 μL/mice was used as the dose. The negative control group 
received PBS. Both, protein and control group immunizations 
were done subcutaneously at the base of the tail, while the live 
vaccine groups received either 107 metacyclic forms of the CL-14 
A2 or the CL-14 wild-type parasite, administered by intraperito-
neal injections. For all protocols, the first dose was administered 
on the day 0, and each group was boosted 4 weeks later, with the 
same immunization dose.
For assessment of immunogenicity, mice (n = 4) were eutha-
nized 21 days after the last vaccination dose. Serum samples and 
spleen of all groups were collected and used to assess, respec-
tively, B and T cell immune responses elicited by the immuni-
zation protocols. Immunized mice (n =  6) were then infected 
subcutaneously, 21 days after the last vaccination dose, into the 
right hind footpad, with 1 × 107 stationary phase promastigotes 
of L. infantum. After challenge (30  days), the animals were 
euthanized; whole spleen was collected, individually processed, 
and used for parasite burden estimation. All experiments were 
performed twice, and representative results of each analysis are 
shown.
immunological assays
For IFN-γ and IL-10 production assays, 1 × 106 splenocytes from 
vaccinated mice were incubated at 37°C and 5% CO2 for 48 h in 
the presence of 10 µg/mL rA2 or RPMI (non-stimulated control). 
The IFN-γ concentrations in the cell culture supernatants were 
determined using OptEIA™ Mouse IFN-γ ELISA Kit (BD, USA), 
according to manufacturer’s instructions. OptEIA™ Mouse IL-10 
ELISA Kit (BD, USA) was used to evaluate IL-10 concentration, 
according to manufacturer’s instructions.
Antibody production was measured by enzyme-linked 
immunosorbent assay (ELISA), using rA2 protein as the coat-
ing antigen, at the concentration of 10 µg/mL. Serum from each 
immunized mouse was diluted 1:50, as established by a previous 
titration curve, and analyzed in duplicate. The reaction was 
developed using horseradish peroxidase-conjugated second-
ary antibodies (anti-IgG, IgG1, and IgG2a) (Zymed, USA) and 
substrate solution (Ortho-phenylenediamine + H2O2 diluted in 
citrate buffer pH 5,0). Optical densities were measured at 492 nm 
in the VersaMax microplate reader (Molecular Devices, USA).
To guarantee that effective immunization using T. cruzi CL-14 
vector were achieved, we also evaluated the antibody response 
directed to the live vaccine vector by ELISA. For this purpose, 
total T. cruzi CL-14 extract was used as the coating antigen at a 
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concentration of 10 µg/mL, and the reaction was developed as 
described above.
estimation of Parasite load
For detection of L. infantum infection, 30 days after the challenge, 
animals were euthanized, and their spleens were harvested for 
parasite quantification by qPCR. DNA extraction of the analyzed 
organs was performed using the Illustra tissue and cells Mini Spin 
Kit (GE Healthcare, UK) according to the manufacturer’s instruc-
tions. After extraction, samples were quantified in a NanoVue 
spectrophotometer (GE Healthcare, UK) and diluted with 
nuclease-free water to a final concentration of 10 ng/µL.
SYBR Green qPCR was performed, as previously described 
(25), with primers targeting the sequences of L. infantum KDNA 
(accession number: EU437407), namely, KDNA fw: 5’ CCT ATT 
TTA CAC CAA CCC CCA GT 3’ and kDNA Rv: 5’ GGG TAG 
GGG CGT TCT GCG AAA 3’ and also Mus musculus β actin 
gene (accession number: NM_007393.5) namely, actin fw: 5’ 
CAG AGC AAG AGA GGC ATC C 3’ and actin Rv: 5’ TCA TTG 
TAG AAG GTG TGG TGC 3’. The qPCR amplification resulted in 
a 116-bp product for the kDNA primers and a 104-bp product for 
the actin β primers. Reactions were performed in a final volume 
of 20  µL, consisting of 1× MAXIMA SYBR Green/ROX qPCR 
Master Mix (Thermo Scientific, USA), 4 nM of each primer, and 
50 ng of DNA template.
Standard curves were performed using eight serial dilutions 
of the target DNA, starting from 500,000–0.05 pg. All samples 
and negative controls were analyzed in duplicates for each run. 
Parasite loads were estimated as the number of Leishmania cells 
in 106 mouse cells. For determination of percentage of protec-
tion, the parasite loads in control PBS mice were considered as 
100%. Reductions in parasite loads in vaccinated mice were then 
converted to percentage values.
sequences comparison
Sequence similarities between optimized A2 and proteins belong-
ing to T. cruzi were accessed using BLASTp (NCBI, USA) analysis 
specific to T. cruzi strain CL Brener (taxid:353153) databank.
statistical analyses
Statistical analyses were performed using GraphPad Prism 
7.0 (GraphPad, CA, USA). For data analysis and comparisons, 
we used one-way ANOVA followed by Tukey’s multiple com-
parisons posttest. p < 0.05 was considered statistically significant 
(*p < 0.05, **p < 0.01, and ***p < 0.001,).
resUlTs
immunogenicity and Protection conferred 
by ra2 Protein
The recombinant A2 antigen has been employed in several 
preclinical studies against leishmaniasis (9, 26) and is also com-
mercially available as a canine vaccine against VL (13, 27). In this 
study, we developed an optimized A2 gene for expression in 
E. coli, including the entire non-repetitive domain of the protein 
and only 10 repeated regions, in contrast to 40–90 repetitions 
from the original sequence (Figure 1A). Therefore, this sequence 
has become more suitable for bacterial expression and should 
maintain the same immunogenicity as the original sequence. 
The protein obtained from E. coli expression followed by affinity 
purification is shown in the Coomassie-stained SDS-PAGE (left 
panel), while the anti-A2 specificity was confirmed by western 
blot analysis (right panel), both showing a band around 25 kDa, 
as expected for the optimized protein (Figure 1B).
To confirm the immunogenicity elicited by the optimized rA2, 
immunization protocols were performed as follows: BALB/c mice 
were immunized with PBS (control group) or rA2 in combina-
tion either with MPLA or CpG B297 plus Alum as adjuvant. To 
assess the humoral immune response, serum from immunized 
mice was subjected to ELISA anti-rA2 for IgG total, IgG1, and 
IgG2a antibody isotypes (Figure 1C). The data show that the rA2 
protein, associated with either MPLA or CpG B297 adjuvants, 
was able to elicit a robust IgG total, IgG1, and IgG2a production, 
as previously observed with the original sequence (26).
Previous studies reporting vaccination strategies against 
Leishmania infection disclosed the importance of cell-mediated 
immunity for protection; specifically, the cellular responses based 
on the IFN-γ production. Therefore, by way of an ELISA assay, we 
measured the levels of IFN-γ present in the supernatants of sple-
nocyte cultures from immunized mice after in vitro stimulation 
with rA2 or RPMI for 48 h. Results showed that the immunization 
with the rA2 antigen associated with MPLA or Alum/CpG led 
to high levels of IFN-γ (Figure 1D), when compared with PBS 
group under rA2 stimuli.
After the ability of the rA2-based vaccines to stimulate a 
Th1-biased T cell response had been confirmed, we tested if such 
immune response could induce protection against challenge with 
L. infantum. For this, parasite burden was evaluated in the spleen 
of mice in each immunization group 30 days after the challenge 
with 1 × 107 L. infantum. The results showed that the optimized 
rA2 antigen was capable of inducing a strong reduction of the 
parasite burden regardless of the adjuvant used (Figure  1E). 
However, these results support the potential use of the optimized 
rA2 antigen as a vaccine candidate for VL.
stably Transfected cl-14 Parasites 
express recombinant a2 Proteins
Aiming to obtain transgenic T. cruzi CL-14 lines, we engineered 
an integrative plasmid with the vector pROCKNeo containing the 
coding sequence for A2 (Figure S1 in Supplementary Material). 
The pROCKNeo backbone contains sequences of homology to 
the abundantly prevalent locus of T. cruzi β-tubulin gene, allow-
ing insertion of a multi-copy transgene into the genome of the 
parasite (23). Successful transfection of the recombinant plasmid 
into the parasite was confirmed via PCR using oligonucleotides 
flanking the A2 coding sequence. PCR results indicate that the 
constructs containing the A2 gene were efficiently inserted into 
(Figure 2A). Plasmids containing the construct (pROCKNeoA2) 
and the genomic DNA, derived from wild-type CL-14, were used, 
respectively, as positive and negative controls.
To confirm whether the neomycin-resistant CL-14 trans-
fected parasites were expressing the recombinant protein, we 
FigUre 1 | Recombinant amastigote 2 (A2) confers immunogenicity and protection against Leishmania infantum challenge in BALB/c mice. (a) Schematic 
representation of the recombinant A2 protein compared with the original A2 sequence present in Leishmania donovani. Boxes represent the C- or N-terminal 
sequences, while the circles represent the repetitive amino acid sequences. Although the codon optimization was performed, it is not represented here.  
(B) Coomassie-stained SDS-PAGE of purified rA2 (left panel) and specific reactivity in Western blot with an anti-A2 monoclonal antibody (right panel). (c) Mice 
immunized s.c. with a homologous prime-boost protocol containing phosphate-buffered saline (PBS; negative control) or 10 µg of rA2 administered along 
monophosphoryl lipid A (MPLA) or Alum/CpG had their serum obtained 21 days after the last immunization dose. Serum samples were individually analyzed by 
enzyme-linked immunosorbent assay (ELISA) for total IgG, IgG1, or IgG2a, as previously described. (D) Mice immunized as previously described were sacrificed 
21 days after the last immunization, and spleen cells were used for IFN-γ analyses by ELISA. For in vitro restimulation, it was used either rA2 or RPMI medium.  
(e) Mice immunized as previously described were euthanized 30 days after the challenge with L. infantum, and spleens were used for parasite loads’ determination 
using qPCR assay. *p < 0.05, **p < 0.01, and ***p < 0.001 analyzed by one-way ANOVA followed by Tukey’s multiple comparison test. Results are expressed as 
the mean and SEM values of duplicate assays using four to six different animals from each group individually analyzed.
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used parasite extracts in western blot analysis. Recombinant A2 
purified protein was loaded as a positive control, and the wild-
type CL-14 extract was used as a negative control. The band 
profiles observed on the blots (Figure  2B) indicate that A2 is 
expressed only in neomycin-resistant parasites transfected with 
pROCKNeoA2. No expression was detected in the control group, 
represented by CL-14 WT. The A2 protein expressed by the trans-
genic CL-14 A2 parasites was further confirmed by immunofluo-
rescence using monoclonal anti-A2 antibodies (Figure 2C). The 
last result supports the western blot data, whereby CL-14 WT 
was negative, and only the transfected parasites was positive for 
the A2 protein.
cl-14-Based live Vaccine induces Potent 
immune responses and lead to 
Protection after L. infantum challenge
After the expression of the rA2 by CL-14 A2 parasite had been 
confirmed, the ability of such vector to elicit specific humoral and 
cellular immune responses in mice was tested. For this purpose, 
we immunized mice with a prime/boost homolog protocol with 
the CL-14 A2, control wild-type CL-14 parasites, and also the 
rA2 protein along with Alum/CpG (Figure S2 in Supplementary 
Material). Negative control mice received only PBS.
With respect to the anti-rA2 humoral immune responses, mice 
immunized with rA2 +  Alum/CpG showed a higher antibody 
response (IgG, IgG1, or IgG2a) when compared to mice immu-
nized with the transgenic or control parasites (Figure 3A). Since 
mice immunized with the parental CL-14 or with the transgenic 
CL-14 A2 induced similar antibody levels to those observed in 
the control groups, we performed an ELISA using the total extract 
of T. cruzi CL-14. This assay was designed to confirm that the 
immunizations using these parasites were efficient. As seen in the 
Figure 3B, serum samples of animals immunized with the CL-14 
parasites (transgenic or otherwise) were able to induce high levels 
of antibodies to the total extract of the CL-14. The same was not 
observed in the serum samples of animals immunized with PBS 
only or the recombinant protein formulations.
FigUre 2 | Transgenic CL-14 parasites stably express recombinant amastigote 2 (A2). (a) Agarose gel electrophoresis of PCR products confirming specific 
amplification of the nucleotide sequences enconding the A2 (963pb) antigen by CL-14 A2 DNA extracts. As a positive control, plasmid DNA containing the 
nucleotide sequence-encoding rA2 was used (see Supplementary Material for plasmid maps). For negative control, we used untransfected CL-14 DNA extract.  
(B) Western blot analysis of transgenic CL-14 parasites lysates confirming the expression of 24 kDa A2. We used rA2 as a positive control. Monoclonal anti-A2 was 
used for detection of A2. (c) Immunofluorescence of fixed untransfected (CL-14 WT) and trasngenic CL-14 A2 parasites. 2 × 105 parasites were washed, fixed, and 
loaded into a poly-l-lysine-coated glass slide. DAPI shows nuclear staining, and the green channel shows protein localization detected by monoclonal anti-A2 with 
AlexaFluor 488 anti-mouse IgG as secondary antibody. The glass slides were analyzed in a LSM Zeiss microscope.
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Considering that IFN-γ is the main cytokine involved in pro-
tection against Leishmania, we evaluated its production by spleen 
cells of mice vaccinated with the different formulations, using an 
ELISA assay, 21 days after the last immunization dose. When rA2 
was used as a stimuli, the animals immunized with the respec-
tive recombinant protein associated with Alum/CpG or with the 
live vaccine (CL-14 A2) were able to produce increased levels of 
IFN-γ when compared to the control group (Figure  3C). 
Interestingly, immunization with the wild-type parasite CL-14 was 
also able to induce significantly increased production of IFN-γ. We 
also measured the levels of IL-10, an important cytokine related 
with parasite persistence in the host. Although increased IL-10 
levels were detected after rA2 stimulation in all immunized groups, 
no significant differences were observed among them (Figure 3D).
Parasite loads in mice of all groups were determined in the 
spleen (Figure 4A) or liver (Figure 4B) by quantitative real-time 
PCR. The results revealed that mice immunized with rA2 + Alum/
CpG (78%) as well as those immunized with control CL-14 (71%) 
and the transgenic parasite expressing A2 (78%) had a significant 
decrease in parasite burden when compared to the control group 
(PBS).
T. cruzi Proteins share similarity with ra2
Since animals immunized with CL-14 were able to produce 
elevated levels of IFN-γ when stimulated with rA2, we asked 
if this protein or its previous predicted epitopes would share 
sequence similarity with CL-14 proteins. Therefore, a BLASTp 
analysis was performed to address if the sequence covering 
most of the described B and T cell epitopes for A2 (SASAEPH -
KA AVDVGPLSVGPQSVGPLSVGPQAVGPLSV) (11) would 
have similarity with T. cuzi proteins. Table 1 shows the BLASTp 
results of proteins that had similarities in the restricted epitope 
sequence.
DiscUssiOn
To date, the best example of long-lasting protection against 
leishmaniasis has been achieved through a previous infection 
with the parasite L. major that usually causes local and benign 
cutaneous lesions, which may spontaneously heal, resulting 
in the induction of cellular immune responses (28). Based 
on this, a technique called leishmanization, consisting on the 
inoculation of infective material from cutaneous wounds, was 
used in the Middle East, to prevent cutaneous leishmaniasis 
(29, 30). The caveats of this procedure include safety issues 
and standardization. However, it indicates that a vaccine 
is feasible and suggests that chances of success are higher 
using a live vector strategy (28) although this issue may be 
eventually circumvented by the use of recombinant protein 
formulations.
FigUre 3 | Prime/boost immunization with CL-14 amastigote 2 (A2) induces an effective immune response in immunized BALB/c mice. (a) Specific antibody 
response (total IgG, IgG1, and IgG2a) induced by each immunization protocol was measured 21 days after the last immunization dose using serum samples of 
immunized mice. (B) Levels of total IgG against the live vaccine vector CL-14 were measured by enzyme-linked immunosorbent assay (ELISA) using serum samples 
of immunized mice. As a coating antigen, 10 µg of total CL-14 antigen extract was used. Mice immunized as previously described were euthanized 21 days after 
the last immunization dose. Spleen cells were cultured, and supernatants were used for IFN-γ (c) or IL-10 (D) analyses by ELISA. For in vitro re-stimulation, we used 
either RPMI or rA2. *p < 0.05, **p < 0.01, and ***p < 0.001 analyzed by one-way ANOVA followed by Tukey’s multiple comparison test. Results are expressed as 
the mean and SEM values of duplicate assays using four to six different animals from each group individually analyzed.
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Nonetheless, the development of clinically protective vaccines 
for VL remains a global challenge (31, 32). The majority of exist-
ing vaccines for bacteria and virus are based on the production of 
specific neutralizing antibodies (33, 34). Conversely, an efficient 
vaccine for intracellular parasitic infections, such as leishmania-
sis, should elicit strong and long-lasting T cell-mediated immu-
nity (35, 36). Therefore, the use of Th1-type adjuvants, including 
toll-like receptors (TLRs) agonists, as well as systems that prolong 
antigen exposure and mimic the infection are important strate-
gies to promote and maintain a T cell-based protective response 
(37, 38).
Among the candidate antigens for second-generation vac-
cines against VL, A2 is a well-established molecule, employed 
in several preclinical leishmaniasis prevention protocols and, in 
combination with saponin, constitute the commercially available 
veterinary vaccine, Leish-Tec®, which is licensed on the Brazilian 
market since 2008 (13, 14, 27). Although extensively tested in 
dogs, the Leish-Tec® formulation cannot be directly transposed 
to human trials, since the adjuvant saponin, which induces lipid 
bodies and cross-presentation by DCs (39), is not approved for 
human use. Therefore, progress toward a human VL vaccine may 
require more specific and safe adjuvants, other than saponin (40). 
In addition, the original A2 sequence has significant drawbacks 
for production in industrial settings that may be circumvented. 
To improve recombinant expression and purification of this 
antigen, we developed an optimized gene coding for a shorter 
homolog of the A2 protein, which contains 10 repetitions, instead 
of the 40–90 repetitions from the original sequence. Codon opti-
mization and the reduction of the repetitive sequences simplified 
the production process of the recombinant protein (41, 42). In 
addition, protein expression efficiency and yields were increased. 
These parameters are especially relevant in the context of quality 
control and high-scale production at industrial settings. Next, we 
tested the optimized A2 protein in different vaccine formulations 
to validate its immunogenicity, when associated with adjuvants 
more suitable for human use to human use. Our results indicated 
high levels of protection in BALB/c mice, by combining A2 
with MPLA or CpG B297, corroborating previous results that 
indicate A2 as a promising candidate antigen, including those of 
preclinical trials in dogs or in Rhesus monkeys, a closer animal 
model to human VL (43). The combination of A2 with MPLA 
and ODN was based on prior evidence that these molecules are 
FigUre 4 | Prime/boost immunization with CL-14 amastigote 2 (A2) induces protection in immunized BALB/c mice 30 days after the challenge animals were 
euthanized, and DNAs extracted from the spleen (a) or liver (B) were used for parasite burden using qPCR assay. The reduction percentage of parasite burden, 
based on the phosphate-buffered saline (PBS) group is shown for each group. *p < 0.05 and ***p < 0.001 analyzed by one-way ANOVA followed by Tukey’s 
multiple comparison test. Results are expressed as the mean and SEM values of duplicate assays using four to six different animals from each group individually 
analyzed.
TaBle 1 | Sequence comparison among rA2 and Trypanosoma cruzi CL Brener proteins.
T. cruzi proteins Protein identity (%) Query cover (%) similar sequences to a2 mapped epitopes: 
SASAEPHKAAVDVGPLSVGPQSVGPLSVGPQAVGPLSVGPQ
Transialidases (XP_808957)  32  91 SAEPEPTK—-VDVGPASV
Transialidase (TcCLB.508247.90) 50 11 VDVASLSVG
Transialidase (XP_808957) 32 91 PKSAEP-KPAE
Hypothetical protein (TcCLB.506863.70) 80 80 LSI-PQSVGP
Hypothetical protein (XP_814399) 50 65 VSPLSAGPQ
Mucin TcMucII (TcCLB.510583.70) 77 47 ASAEPEHK—VDV
Amino acid permease (XP_814539.1)  24 54 VGVQVVGTLSVG
Zeta tubulin (XP_817160) 62 76 VAPQAVGELS
Surface protease GP63 (XP_804359.1) 58 70 AVGALNFGPQ
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TLR4 and TLR9 agonists, respectively, with the ability to trigger 
Th1 responses (44). In addition, both TLRs are activated during 
L. donovani infection (45). Of note is the fact that the protection 
levels induced by the rA2/CpG B297 formulation against experi-
mental VL were higher than those previously described in BALB/c 
mice immunized with formulations containing saponin, includ-
ing the commercial Leish-Tec® vaccine (46). Although CpGs 
had emerged as good inducers of Th1 immune responses, the 
combined formulation with Alum increases the antigen/adjuvant 
depots, leading to an improved uptake by professional presenting 
cells, strengthening specific immune responses (47). CpG B297 
is an ODN present in T. cruzi that is associated with enhanced 
Th1-type adjuvant activity, compared to other standard bacte-
rial CpGs (24). More specifically, the rational selection of CpG 
B297 was founded on the recognition of this molecule by TLR9 
homologs in both mice and human cells (24, 48). In contrast to 
MPLA, which is a bacterial-derived molecule, or saponin, which 
is purified from Quillaja saponaria, the synthetic nature of CpG 
B297 may circumvent problems generally associated with other 
adjuvants, including scale production and the lack of endotoxin 
or other contaminants, thus improving safety. Therefore, the 
use of CpG B297 molecule may more easily translate results of 
preclinical tests to human clinical trials, turning more feasible 
significant step toward a human vaccine.
The IFN-γ cytokine is the main Th1 marker associated with 
host protection in VL infection (49, 50). Induction of high levels of 
antigen-specific IFN-γ was detected for the groups receiving rA2, 
as well as CL-14 WT and transgenic CL-14 A2 vaccinated groups. 
Surprisingly, the group immunized with the CL-14 reference strain 
produced elevated levels of IFN-γ, when stimulated with A2. This 
intriguing result led us to search for sequence similarities among 
A2 predicted epitopes and T. cruzi proteins. Common epitopes 
for B cells are known among trypanosomatids and, depending of 
the transmission areas and the diagnostic test used, may hamper 
specific diagnosis between T. cruzi and Leishmania spp infections 
(51). Therefore, it is plausible that common T cell epitopes might 
be shared by these parasites, with different degrees of affinities 
for TCRs. Partial similarity was observed among the sequence 
SASAEPHKAAVDVGPLSVGPQSVGPV, which contains the A2 
B and T cell CD4+ and CD8+ mapped epitopes (11), and short 
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amino acid sequences present in trans-sialidases, mucin, amino 
acid permease, GP63, and hypothetical proteins of T. cruzi, which 
may be potential T cell epitopes. Although these findings require 
further experimental support, they may explain why cells from 
CL-14 vaccinated animals produced IFN-γ upon rA2 stimula-
tion. Among these proteins, members of the trans-sialidase 
superfamily are widely studied as antigen candidates for vaccina-
tion against Chagas disease since they lead to robust humoral 
and CD8+ T  cell-mediated immunity (52–55). In addition to 
these potential T  cell epitopes, the T. cruzi CL-14 parasite has 
several immunomodulators, such as glycoinositolphospholipids 
and CpG ODNs (24, 56), explaining why the live vaccine possess 
intrinsic adjuvant properties.
Low levels of antigen-specific antibodies were observed for 
the CL-14 vaccinated groups. Other vaccine vectors that elicit 
Th1-biased responses favoring antigen presentation by MHC 
class I and activation of CD8+ T  cell, such as adenovirus or 
plasmid DNA, also lead to low antibody induction depending 
on the administration protocol (43). In contrast, the vaccina-
tion with the rA2 in combination with alum and CpG B297 
led to high levels of antigen-specific total IgG, IgG1, and 
IgG2 antibodies. Generation of antibody-based response was 
expected for recombinant protein vaccines, as observed in 
previous studies testing these antigens (9–11, 13, 14, 57). In 
addition, aluminum salt adjuvants favor antibody production 
(58). Although questions remain about the mechanism of alum-
driven immunomodulation (59), its combination with Th1 type 
adjuvants can result in both antibody production and increased 
IFN-γ levels. This pattern was observed in studies with cancer 
(18) and dengue virus (60) antigens in formulations containing 
alum plus CpG.
Immunization with CL-14 or recombinant CL-14 A2 parasites 
elicited a strong Th1-based cell immunity and displayed protec-
tion against a L. infantum challenge in BALB/C mice, suggesting 
CL-14 as a potential vaccine candidate for VL. Several factors 
justify the use of CL-14 as a live vaccine for leishmaniasis: (i) a 
great number of genes are shared by trypanosomatids; (ii) there 
is a similar intracellular biological cycle, favoring a CD8 T cell 
induction; (iii) T. cruzi has natural immunostimulatory mol-
ecules; and (iv) the long exposure time improves the generation 
of long-lasting immunity (18, 24, 48, 56). There are also other 
examples of leishmaniasis vaccine candidates based on non-
pathogenic live parasites (28). Among them, Leishmania taren­
tolae is a non-pathogenic species to humans, also of particular 
interest. This lizard-infecting species is not able to persist long 
enough in mammalian host to cause infection, even in immuno-
compromised mice. However, this parasite alone is able to induce 
DC maturation, elicit Th1-type response, and induce partial cross 
protection against L. donovani challenge (61). Therefore, L. taren­
tolae has been tested as a vaccine vector and recombinant parasite 
expressing different heterologous antigens, including A2, which 
led to protection in mice (10, 62–64) and dogs (36). A major 
concern with live vaccination strategies is related to safety issues. 
For CL-14, this topic has been addressed many times. In tests with 
newborn mice, which are very susceptible to Chagas infection, no 
parasite was found in tissue or blood after inoculation of CL-14 
(18, 65). In addition, in experiments with knockout mice, lacking 
important immunologic mechanisms, such as CD8+ T  cells, 
CL-14 was unable to generate disease (7). Regardless these safety 
issues, successful vaccination studies using live vectors have been 
also reported for other parasitic diseases such as malaria (66) 
and toxoplasmosis (67, 68). Noteworthy, the most promising 
malaria vaccine, which is in advanced clinical trial, is based on 
i.v. administration of radio-attenuated sporozoites (69). CL-14 
was previously reported protective against Chagas disease and 
cancer, when expressing NY-ESO antigen (18, 24). Our results 
confirm the potential of live vaccination strategies for VL, specifi-
cally with the CL-14 model, increasing its range of target diseases. 
Nevertheless, even if the translation of this live vaccine candidate 
as a licensed human vaccine would not be feasible, the reported 
T. cruzi CL-14 data add important contribution to the vaccino-
logy field, showing the potential of a multi-protozoa vaccine, 
which may favor future development of alternative vaccines for 
such complex diseases.
Together, our results support the success of the newly designed 
rA2 vaccine formulations and the T. cruzi CL-14 to induce strong 
T  cell-mediated immune responses and protection against VL 
in animal models. Both vaccination strategies reveal promising 
alternatives for the development of new vaccine formulations 
for VL. On one hand, the CL-14 data expand the evidence that 
live vaccine vectors may be useful to induce cross protective 
responses and development of multiparasite vaccines; however, 
the A2 recombinant protein formulation is a more feasible vac-
cine to progress to human clinical trials.
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